This essential work, edited by two researchers at London s famous Queen Mary s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes.

Part 1: Introduction

Historical Development of Monoclonal Antibody Therapeutics. Preclinical Safety Evaluation of Monoclonal Antibodies
Part II: Molecular Developments in Antibody Production
Engineering Antibodies for Stability and Efficient Folding. Human Monoclonal Antibodies from Transgenic Mice
Part III: Antibodies to Cytokines
Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future. Therapeutic Anti-VEGF Antibodies. Humanized Anti-human IL-6 Receptor Antibody, Tocilizumab
Part IV: Antibodies to Cell Markers
Anti-CD20 Monoclonal Antibody in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Herceptin. The Use of CD3-Specific Antibodies in Autoimmune Diabetes: A Step Towards the Induction of Immune Tolerance in the Clinic. Monoclonal Antibody Therapy for Prostate Cancer. Anti-IgE and other Antibody Targets in Asthma
Part V: Development of Antibody-Based Cellular and Molecular Therapies
Cytokine, Chemokine, and Co-stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors. The T-Body Approach: Redirecting T-Cells with Antibody Specificity. Intracellular Antibodies (Intrabodies) as Specific Molecules for Therapeutic Applications.